In the exploration of aging and health outcomes, epigenetic clocks have emerged as crucial biomarkers. Predominantly developed from data pertaining to ...
Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.
Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.